文献速递中医内科中药与中成药合理使用

夏枯草口服液联合西药治疗Graves病的系统评价与Meta分析

Prunella Oral Liquid in combination with Western medical treatment for Graves' disease: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2026-07-29

该研究检索7个数据库至2025年9月的随机对照试验,纳入9项RCT共966例Graves病患者,评价夏枯草口服液联合西药治疗的疗效与安全性。Meta分析显示联合治疗在降低甲状腺激素、抗体水平、缩小甲状腺体积及减少不良事件方面可能优于单用西药,但证据质量多为低至极低,结论需谨慎解读。

要点

  • 夏枯草口服液联合抗甲状腺药可进一步降低FT3、FT4、TRAb、TgAb并升高TSH。
  • 联合治疗可缩小甲状腺各径线及峡部厚度,并降低不良事件风险(RR=0.35)。
  • 证据质量多为低至极低,分配隐藏与盲法不足,需谨慎解读。

核心结论

  • 夏枯草口服液联合西药治疗可能为Graves病患者提供额外临床获益,但因证据质量低且存在方法学局限,结论需谨慎解读。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库自建库至2025年9月的RCT,手工检索参考文献,采用Cochrane RoB 1.0评估偏倚风险,RevMan 5.4分析,GRADE框架评价证据质量。
  • 共纳入9项RCT,涉及966例Graves病患者,所有试验均比较夏枯草口服液联合西药与单纯西药治疗。

主要发现

  • 与单用抗甲状腺药(ATD)相比,夏枯草口服液联合ATD进一步降低FT3(SMD=-0.94,95%CI[-1.63,-0.26])和FT4(SMD=-0.87,95%CI[-1.55,-0.19]),升高TSH(SMD=0.79,95%CI[0.31,1.27])。
  • 联合ATD还降低TRAb(SMD=-1.26,95%CI[-1.69,-0.83])和TgAb(IU/mL)(MD=-105.33,95%CI[-128.03,-82.63]),并降低不良事件风险(RR=0.35,95%CI[0.13,0.94])。
  • 联合ATD缩小甲状腺右叶前后径(cm)(MD=-0.28,95%CI[-0.39,-0.17])、左叶前后径(cm)(MD=-0.27,95%CI[-0.42,-0.12])、右叶横径(cm)(MD=-0.23,95%CI[-0.31,-0.15])、左叶横径(cm)(MD=-0.25,95%CI[-0.32,-0.18])、右叶纵径(cm)(MD=-0.44,95%CI[-0.65,-0.22])、左叶纵径(cm)(MD=-0.70,95%CI[-0.93,-0.48])及峡部厚度(cm)(MD=-0.14,95%CI[-0.17,-0.11])。
  • 与单用碘-131(131I)相比,夏枯草口服液联合131I进一步降低TRAb(U/mL)(MD=-17.00,95%CI[-20.02,-13.98])、TgAb(U/mL)(MD=-132.00,95%CI[-149.75,-114.25])和TPOAb(SMD=-2.98,95%CI[-4.29,-1.67])。
  • 夏枯草口服液联合ATD加营养补充剂进一步降低FT3(pmol/L)(MD=-0.93,95%CI[-1.42,-0.44])并升高TSH(μIU/mL)(MD=0.17,95%CI[0.07,0.27])。

关键数值与推荐

  • 与单用ATD相比,联合治疗降低FT3的SMD=-0.94(95%CI[-1.63,-0.26]),降低FT4的SMD=-0.87(95%CI[-1.55,-0.19]),升高TSH的SMD=0.79(95%CI[0.31,1.27])。
  • 联合ATD降低TRAb的SMD=-1.26(95%CI[-1.69,-0.83]),降低TgAb(IU/mL)的MD=-105.33(95%CI[-128.03,-82.63]),不良事件风险RR=0.35(95%CI[0.13,0.94])。
  • 与单用131I相比,联合治疗降低TRAb(U/mL)的MD=-17.00(95%CI[-20.02,-13.98]),降低TgAb(U/mL)的MD=-132.00(95%CI[-149.75,-114.25]),降低TPOAb的SMD=-2.98(95%CI[-4.29,-1.67])。
  • GRADE证据质量范围为低至极低。

临床怎么用

  • 在Graves病患者中,可考虑在规范西药(ATD或131I)治疗基础上联合夏枯草口服液以辅助改善甲状腺功能、抗体水平及甲状腺肿大。
  • 联合治疗可能降低不良事件风险,但需结合患者个体情况及证据局限性综合决策。

局限性

  • 偏倚风险主要源于分配隐藏不明确及缺乏盲法导致的实施偏倚。
  • GRADE证据质量范围为低至极低,结论需谨慎解读。
  • 需设计严谨、方案标准化的多中心RCT进一步确认疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Prunella Oral Liquid is a Chinese patent medicine prepared from Prunella vulgaris L. Modern pharmacological studies indicate that its primary active constituents, such as rosmarinic acid, possess significant anti-inflammatory, immunomodulatory, and antioxidant properties. Although it is widely used in clinical practice for Graves' disease (GD), uncertainty remains. AIM OF THE STUDY: This study aimed to evaluate the efficacy and safety of Prunella Oral Liquid in patients with GD. MATERIALS AND METHODS: We searched seven databases for the randomized controlled trials (RCTs) of Prunella Oral Liquid on GD patients from inception to September 2025, and references in the literature were hand searched. Risk of bias was assessed using the Cochrane RoB 1.0. Data analysis was performed using RevMan 5.4. The certainty of evidence was evaluated with the GRADE framework. RESULTS: Nine RCTs involving 966 patients were included. All included trials compared Prunella Oral Liquid in combination with Western medical treatment with the corresponding Western medical treatment alone. Compared to antithyroid drug (ATD) alone, Prunella Oral Liquid combined with ATD further reduced FT3 (SMD = -0.94, 95%CI [-1.63,-0.26]) and FT4 (SMD = -0.87, 95%CI [-1.55, -0.19]), increased TSH (SMD = 0.79, 95%CI [0.31,1.27]), lowered TRAb (SMD = -1.26, 95%CI [-1.69,-0.83]) and TgAb (IU/mL) (MD = -105.33, 95%CI [-128.03,-82.63]), decreased the anteroposterior diameter of the right thyroid lobe (cm) (MD = -0.28, 95%CI [-0.39,-0.17]), the anteroposterior diameter of the left thyroid lobe (cm) (MD = -0.27, 95%CI [-0.42,-0.12]), the transverse diameter of the right thyroid lobe (cm) (MD = -0.23, 95%CI [-0.31,-0.15]), and the transverse diameter of the left thyroid lobe (cm) (MD = -0.25, 95%CI [-0.32,-0.18]), the longitudinal diameter of the right thyroid lobe (cm) (MD = -0.44, 95%CI [-0.65,-0.22]), the longitudinal diameter of the left thyroid lobe (cm) (MD = -0.70, 95%CI [-0.93,-0.48]), the thyroid isthmus thickness (cm) (MD = -0.14, 95%CI [-0.17,-0.11]), and lowered risk of adverse events (RR = 0.35, 95%CI [0.13,0.94]). Compared with Iodine-131 (131I) alone, Prunella Oral Liquid plus 131I further reduced TRAb (U/mL) (MD = -17.00, 95%CI [-20.02,-13.98]), TgAb (U/mL) (MD = -132.00, 95%CI [-149.75,-114.25]), and TPOAb (SMD = -2.98, 95%CI [-4.29,-1.67]). Prunella Oral Liquid, when used in combination with ATD plus nutritional supplements, further reduced FT3 (pmol/L) (MD = -0.93, 95%CI [-1.42,-0.44]), and increased TSH (μIU/mL) (MD = 0.17, 95%CI [0.07,0.27]). Risk of bias was primarily attributable to unclear allocation concealment and performance bias due to lack of blinding. According to GRADE, the certainty of evidence ranged from low to very low. CONCLUSIONS: Prunella Oral Liquid combined with Western medical treatment may provide additional clinical benefits for patients with GD. Given the low certainty of evidence and methodological limitations identified, these findings should be interpreted with caution. Rigorously designed multicenter RCTs with standardized protocols are needed to confirm its efficacy and safety.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Chen Z, Yuan B, Zhang L, et al. Prunella Oral Liquid in combination with Western medical treatment for Graves' disease: A systematic review and meta-analysis. J Ethnopharmacol. 2026. PMID: 42526549. doi:10.1016/j.jep.2026.122255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。